VEGFA and neoplasm: Heterogeneity in regorafenib response on the other hand may also be a product of differential sensitivities to paracrine tumour-vessel signalling inhibition, as demonstrated by the striking correlation of regorafenib induced tumour neo-vessel inhibition and production of VEGFA by the respective cell lines.